How long does Mounjaro take to suppress appetite?

Appetite changes can appear as early as the first week, but a sustained shift in hunger is more typical from week two onwards.
Tirzepatide works on two gut-hormone pathways (GIP and GLP-1) slowing gastric emptying and increasing fullness signals, which together reduce the drive to eat.
The suppression effect tends to strengthen at each dose increase; the starter dose of 2.5 mg is designed to settle the body, not to deliver maximum appetite control.
If appetite suppression feels absent after several weeks at a stable dose, that is worth raising with your prescriber — there are reasons it may be blunted, and they are addressable.

Mounjaro (tirzepatide) typically begins to reduce appetite within the first one to two weeks of starting treatment, though most people notice a meaningful difference in hunger and fullness cues during weeks two to four. The effect builds gradually as your body adjusts to the medicine — and for many, the clearest changes come after a dose increase. These are prescription-only medicines; a prescriber assesses whether treatment is clinically appropriate for you before anything is dispensed.

Starting from £29.99/mo

Free 2-minute consultation · Reviewed same day

Start journey
The nume Promise

Order by 12pm.

At your door the next working day.
Free, tracked, plain packaging.

Guaranteed on approved orders

Where are you starting from?

BMI isn't the whole story, but it's where clinicians start. Check yours in ten seconds — nothing is stored, nothing is shared.

Check your BMI.

Ten seconds. Private — nothing is stored or shared.

80 kg
170 cm

Your result updates live in the card alongside.

Your result

Your BMI is

which is in the healthy weight range

Start journey

BMI doesn't determine eligibility — only a clinician can assess whether treatment is right for you.

Treatment options

Weight loss treatments

The problem

Most weight loss services treat you like a transaction, a checkout, a courier, and you're on your own.

Algorithm approvalsNo real clinicianGeneric dosingHidden feesSlow deliverySilence after checkout

The nume way

We built the opposite: one clinician who knows you, guaranteed care at every step.

24 hrs

clinician review. Free next working day delivery.

How it works

From consultation to your door, properly.

Tell us about your health, history and goals. Free, online, and confidential — no commitment, no waiting room.

Our team reviews your health the same day — never an algorithm, and approves your treatment there and then if eligible.

Order by 12pm, dispatched same day, delivered free the next working day — the nume Promise.

What the evidence and clinical experience tell us about tirzepatide and appetite

When do most people first notice Mounjaro reducing their appetite?

The honest answer is: it varies more than most content suggests. Some people notice a quietening of hunger signals within the first few days, food feels less urgent, portions feel more filling. Others reach week three or four before they notice anything definitive. Neither pattern is a failure.

The mechanism helps explain the timing. Tirzepatide activates both GLP-1 and GIP receptors, slowing the rate at which food leaves your stomach and signalling satiety to the brain. That dual-receptor action is what makes Mounjaro the only medicine of its kind licensed for weight management in the UK, but the body needs time to respond to these new signals. The NHS tirzepatide patient information page describes how the medicine works, and the clinical picture it draws is one of progressive effect rather than a switch being flipped.

The SURMOUNT-1 trial (which involved 2,539 adults and ran for 72 weeks) recorded average body-weight reductions of around 20–21% at the 15 mg maintenance dose. That kind of result takes months, not days. The appetite changes that drive it accumulate in the same way. If you are at the beginning and not yet feeling much, you are almost certainly still in the adjustment window.

Does the appetite suppression get stronger at higher doses?

Generally, yes. The 2.5 mg starting dose exists primarily to help your digestive system adapt; its job is to reduce early nausea and GI discomfort, not to deliver peak appetite control. Many people find that hunger shifts more noticeably after moving to 5 mg, and again after each subsequent increase.

This is one of the more useful things to understand about how tirzepatide works over time: the appetite-suppressing effect is dose-dependent. Prescribers typically titrate in four-week steps, and the guidance from the NICE technology appraisal TA1026 for tirzepatide reflects that meaningful clinical effect is evaluated at the highest tolerated dose rather than the starting one. So if you are on 2.5 mg and waiting, the fuller picture may not arrive until you have been titrated upward.

That said, some people do experience notable appetite suppression at lower doses, and some find the GI side effects at higher doses harder to manage. The right dose for you is a clinical judgement. Worth knowing this when setting your expectations at week one.

Why might appetite suppression feel inconsistent, or take longer than expected?

A few things can blunt or delay the effect, and they are worth knowing about.

First, the timing in your weekly cycle matters. Tirzepatide is a once-weekly injection, and how quickly Mounjaro suppresses appetite tends to vary across the week, with effects strongest in the first few days after each dose and easing towards the end. If you are comparing your hunger on day six to day two, the difference can feel significant. That weekly rhythm settles for most people over time.

Second, stress, poor sleep and ultra-processed food patterns all work against the satiety signals the medicine is trying to strengthen. Tirzepatide is licensed alongside a reduced-calorie diet and increased activity, not as a replacement for either. Our full Mounjaro overview covers the lifestyle factors that support the medicine's effect.

Third, some people are metabolically slower to respond. If appetite suppression feels genuinely absent after several weeks at a stable dose, that conversation belongs with your prescriber. There is a separate page on what to do if Mounjaro appetite suppression is not working that goes into more detail.

We recognise that waiting for a medicine to do what you hoped it would do can be genuinely frustrating, particularly if you have spent years trying other approaches. That frustration is real and understandable. It is also, for most people, temporary.

What happens to appetite suppression as treatment continues?

For the majority of people, appetite suppression stabilises rather than disappears as they reach their maintenance dose. The acute GI effects (nausea especially) tend to ease, while the fuller-faster feeling persists. That is the intended pattern: the body tolerates the medicine better over time without losing the appetite-regulating benefit.

It is also worth knowing that coming off tirzepatide reverses this process. Appetite typically returns towards baseline over weeks, which is why the question of how to stop Mounjaro without gaining weight deserves careful planning with your prescriber rather than an abrupt stop.

If you are weighing up whether tirzepatide is the right route, understanding the broader timeline for when Mounjaro takes effect across different outcomes (not just appetite) may help. And if you are curious about what the treatment options currently available look like side by side, that is a reasonable place to start before a consultation.

Tirzepatide is a prescription-only medicine. A GPhC-registered prescriber at a regulated pharmacy reviews your clinical information before treatment can be prescribed. If you would like to find out whether you are eligible, you can start a free consultation with our clinical team, reviewed the same day.

Looking to start your weight loss journey?
Take a quick eligibility quiz to explore your options and see how we can support you.
Start free consultation

The people

Meet the team.

Mahommed Zunaid Ayub Patel

Superintendent Pharmacist (GPhC No. 2217101)

Accountable for the safe running of our registered pharmacy, from every dispensing check to every dispatch.

Mostafa Damghani

Clinical Lead (GPhC No. 2231744)

Sets our clinical standards and checks everything we publish against current MHRA guidance.

Shelan Salih

Independent Prescriber (GPhC No. 2084501)

Personally reviews consultations and assesses whether treatment is clinically appropriate, and leads dose adjustments and follow-up checks.

Rehenaaz Uddin

Independent Prescriber (GPhC No. 2083426)

Personally reviews consultations and assesses whether treatment is clinically appropriate, and leads dose adjustments and follow-up checks.

Frequently asked questions